Molecular pattern of ductal pancreatic cancer

被引:43
|
作者
Sirivatanauksorn, V
Sirivatanauksorn, Y
Lemoine, NR [1 ]
机构
[1] Hammersmith Hosp, Imperial Coll, Sch Med,Mol Pathol Lab, Imperial Canc Res Fund,Mol Oncol Unit, London W12 0NN, England
[2] Hammersmith Hosp, Imperial Coll, Sch Med, Div Surg Anaesthet & Intens Care, London W12 0NN, England
关键词
pancreatic cancer; oncogene; tumour suppressor gene; growth factors; growth factor receptors;
D O I
10.1007/s004230050101
中图分类号
R61 [外科手术学];
学科分类号
摘要
Our understanding of the molecular pathology underlying the development and progression of ductal pancreatic cancer has been revolutionised during the last 5 years due to the spectacular development of novel molecular biological techniques. In the present article, we describe key molecular alterations of sporadic and inherited ductal pancreatic cancer. Overexpression of growth factors and growth factor receptors are present in a significant proportion of this tumour type. Mutation of the K-ras oncogene, and disruption of p53 or p16 tumour suppressor gene abrogates the control of the cyclin-dependent kinases (cdk) and retinoblastoma (Rb) gene pathway, causing continuous growth of the pancreatic tumour. Inactivation of the SMAD4 tumour suppressor gene leads to loss of the inhibitory influence of the transforming growth factor beta signalling pathway. Lost or decreased expression of retinoid receptors and failure of telomerase activity may play a role in pancreatic carcinogenesis. Tumour-associated proteinases, matrix metalloproteinases and plasminogen activators are reported to be involved in pancreatic cancer invasion and metastasis. Furthermore, the cytogenetic changes in this cancer are summarised. This molecular pattern distinguishes pancreatic cancer from other epithelial rumours and represents a promising basis for the development of diagnostic and other clinical applications.
引用
收藏
页码:105 / 115
页数:11
相关论文
共 50 条
  • [31] HISTOLOGIC AND MOLECULAR SIMILARITIES IN BILIARY AND PANCREATIC DUCTAL CARCINOMAS
    LONGNECKER, DS
    TERHUNE, PG
    FASEB JOURNAL, 1995, 9 (04): : A852 - A852
  • [32] Possible Molecular Markers for the Diagnosis of Pancreatic Ductal Adenocarcinoma
    Shen, Quan
    Yu, Miao
    Jia, Jiang-Kun
    Li, Wen-Xi
    Tian, Yu-Wei
    Xue, Huan-Zhou
    MEDICAL SCIENCE MONITOR, 2018, 24 : 2368 - 2376
  • [33] Molecular Pathological Phenotypes and Outcome in Pancreatic Ductal Adenocarcinoma
    Jamieson, Nigel B.
    Mohamed, Mohamed A.
    Oien, Karin
    Duthie, Fraser
    Dickson, Euan J.
    Carter, Ross
    McKay, Colin
    GASTROENTEROLOGY, 2013, 144 (05) : S1059 - S1059
  • [35] Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
    Qian, Yunzhen
    Gong, Yitao
    Fan, Zhiyao
    Luo, Guopei
    Huang, Qiuyi
    Deng, Shengming
    Cheng, He
    Jin, Kaizhou
    Ni, Quanxing
    Yu, Xianjun
    Liu, Chen
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [36] Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers
    Taherian, Mehran
    Wang, Hua
    Wang, Huamin
    CELLS, 2022, 11 (19)
  • [37] Molecular pathogenesis of pancreatic ductal adenocarcinoma and clinical implications
    Magee, CJ
    Greenhalf, W
    Howes, N
    Ghaneh, P
    Neoptolemos, JP
    SURGICAL ONCOLOGY-OXFORD, 2001, 10 (1-2): : 1 - 23
  • [38] The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping
    Lautizi, Manuela
    Baumbach, Jan
    Weichert, Wilko
    Steiger, Katja
    List, Markus
    Pfarr, Nicole
    Kacprowski, Tim
    NAR CANCER, 2022, 4 (04):
  • [39] Molecular pathogenesis of precursor lesions of pancreatic ductal adenocarcinoma
    Biankin, AV
    Kench, JG
    Dijkman, FP
    Biankin, SA
    Henshall, SM
    PATHOLOGY, 2003, 35 (01) : 14 - 24
  • [40] Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
    Yunzhen Qian
    Yitao Gong
    Zhiyao Fan
    Guopei Luo
    Qiuyi Huang
    Shengming Deng
    He Cheng
    Kaizhou Jin
    Quanxing Ni
    Xianjun Yu
    Chen Liu
    Journal of Hematology & Oncology, 13